120 related articles for article (PubMed ID: 38032111)
1. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer.
Kos FJ; Frankel P; Cristea M; Eng M; Tinsley R; Dempsey S; Ruel N; Stewart D; Dellinger TH; Diamond DJ
Cancer Res Commun; 2023 Dec; 3(12):2585-2595. PubMed ID: 38032111
[TBL] [Abstract][Full Text] [Related]
2. p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
Hardwick NR; Frankel P; Ruel C; Kilpatrick J; Tsai W; Kos F; Kaltcheva T; Leong L; Morgan R; Chung V; Tinsley R; Eng M; Wilczynski S; Ellenhorn JDI; Diamond DJ; Cristea M
Clin Cancer Res; 2018 Mar; 24(6):1315-1325. PubMed ID: 29301826
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.
Chung V; Kos FJ; Hardwick N; Yuan Y; Chao J; Li D; Waisman J; Li M; Zurcher K; Frankel P; Diamond DJ
Clin Transl Oncol; 2019 Mar; 21(3):363-372. PubMed ID: 30094792
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
Liao JB; Gwin WR; Urban RR; Hitchcock-Bernhardt KM; Coveler AL; Higgins DM; Childs JS; Shakalia HN; Swensen RE; Stanton SE; Tinker AV; Wahl TA; Ancheta RG; McGonigle KF; Dai JY; Disis ML; Goff BA
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531249
[TBL] [Abstract][Full Text] [Related]
5. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract][Full Text] [Related]
6. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.
Hardwick NR; Carroll M; Kaltcheva T; Qian D; Lim D; Leong L; Chu P; Kim J; Chao J; Fakih M; Yen Y; Espenschied J; Ellenhorn JD; Diamond DJ; Chung V
Clin Cancer Res; 2014 Sep; 20(17):4459-70. PubMed ID: 24987057
[TBL] [Abstract][Full Text] [Related]
7. Overcoming immunosuppression to enhance a p53MVA vaccine.
Hardwick N; Chung V; Cristea M; Ellenhorn JD; Diamond DJ
Oncoimmunology; 2014 Nov; 3(10):e958949. PubMed ID: 25941580
[TBL] [Abstract][Full Text] [Related]
8. ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Herzog TJ; Hays JL; Barlin JN; Buscema J; Cloven NG; Kong LR; Tyagi NK; Lanneau GS; Long BJ; Marsh RL; Seward SM; Starks DC; Welch S; Moore KN; Konstantinopoulos PA; Gilbert L; Monk BJ; O'Malley DM; Chen X; Dalal R; Coleman RL; Sehouli J
Future Oncol; 2023 Jul; 19(23):1577-1591. PubMed ID: 37334673
[TBL] [Abstract][Full Text] [Related]
9. Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.
Yuan Y; Kos FJ; He TF; Yin HH; Li M; Hardwick N; Zurcher K; Schmolze D; Lee P; Pillai RK; Chung V; Diamond DJ
Oncoimmunology; 2017; 6(12):e1363138. PubMed ID: 29209571
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
Overman M; Javle M; Davis RE; Vats P; Kumar-Sinha C; Xiao L; Mettu NB; Parra ER; Benson AB; Lopez CD; Munugalavadla V; Patel P; Tao L; Neelapu S; Maitra A
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114502
[TBL] [Abstract][Full Text] [Related]
11. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
Zamarin D; Walderich S; Holland A; Zhou Q; Iasonos AE; Torrisi JM; Merghoub T; Chesebrough LF; Mcdonnell AS; Gallagher JM; Li Y; Hollmann TJ; Grisham RN; Erskine CL; Block MS; Knutson KL; O'Cearbhaill RE; Aghajanian C; Konner JA
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503949
[TBL] [Abstract][Full Text] [Related]
12. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Nijman HW; van Poelgeest MI; van Erkel AR; Smit VT; Daemen TA; van der Hoeven JJ; Melief CJ; Welters MJ; Kroep JR; van der Burg SH
Oncotarget; 2015 Oct; 6(31):32228-43. PubMed ID: 26334096
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Varga A; Piha-Paul S; Ott PA; Mehnert JM; Berton-Rigaud D; Morosky A; Yang P; Ruman J; Matei D
Gynecol Oncol; 2019 Feb; 152(2):243-250. PubMed ID: 30522700
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.
Kuang C; Park Y; Augustin RC; Lin Y; Hartman DJ; Seigh L; Pai RK; Sun W; Bahary N; Ohr J; Rhee JC; Marks SM; Beasley HS; Shuai Y; Herman JG; Zarour HM; Chu E; Lee JJ; Krishnamurthy A
Clin Epigenetics; 2022 Jan; 14(1):3. PubMed ID: 34991708
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer.
Andrikopoulou A; Liontos M; Skafida E; Koutsoukos K; Apostolidou K; Kaparelou M; Rouvalis A; Bletsa G; Dimopoulos MA; Zagouri F
Int J Gynecol Cancer; 2023 Apr; 33(4):571-576. PubMed ID: 36604119
[TBL] [Abstract][Full Text] [Related]
16. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
How JA; Jazaeri A; Westin SN; Sood AK; Ramondetta LM; Xu M; Abonofal A; Karp DD; Subbiah V; Stephen B; Rodon JA; Yang F; Naing A
Invest New Drugs; 2021 Jun; 39(3):829-835. PubMed ID: 33415580
[TBL] [Abstract][Full Text] [Related]
17. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
[TBL] [Abstract][Full Text] [Related]
19. Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid.
Portnow J; Wang D; Blanchard MS; Tran V; Alizadeh D; Starr R; Dodia R; Chiu V; Brito A; Kilpatrick J; McNamara P; Forman SJ; Badie B; Synold TW; Brown CE
JAMA Oncol; 2020 Dec; 6(12):1947-1951. PubMed ID: 33030521
[TBL] [Abstract][Full Text] [Related]
20. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]